Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

HepG2 and SK-N-MC: Two Human Models to StudyAlpha-2 Adrenergic Receptors of theAlpha-2C Subtype

Stéphane Schaak, Cécile Cayla, Régis Blaise, Françoise Quinchon and Hervé Paris
Journal of Pharmacology and Experimental Therapeutics May 1997, 281 (2) 983-991;
Stéphane Schaak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cécile Cayla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Régis Blaise
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Françoise Quinchon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hervé Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

It is now clearly established that alpha-2 adrenergic receptors can be subdivided in three pharmacological subtypes (alpha-2A, alpha-2B andalpha-2C) encoded by distinct genes (α2C10, α2C2 and α2C4, respectively, in humans). Whereas the study of the regulation of the human alpha-2A adrenergic receptor and of the promoter region of the α2C10 gene has being greatly helped by the availability of the colon carcinoma cell line HT29, the study of the other human receptor subtypes has thus far been limited to homologous desensitization/down-regulation in transfected cells, because of the lack of human cellular models constitutively expressingalpha-2B or alpha-2C adrenergic receptors. Several human cell lines were thus screened, in an attempt to find such models. Radioligand binding studies with [3H]RX821002 and [3H]MK912, reverse transcription-polymerase chain reactions and RNase mapping experiments with pairs of primers and riboprobes specific for each subtype demonstrated that the hepatoma cell line HepG2 and the neuroblastoma cell line SK-N-MC possess alpha-2 adrenergic receptors of the alpha-2C subtype. However, whereas HepG2 expresses exclusively alpha-2C receptors (55 ± 7 fmol of [3H]MK912 binding sites/mg of protein), SK-N-MC expresses both alpha-2A and alpha-2C subtypes in fairly similar amounts (20 ± 8 and 23 ± 3 fmol of [3H]MK912 binding sites/mg of protein, respectively). The study of the inhibition of 3H-labeled antagonist binding by UK14304 demonstrated that a fraction of the receptor population was coupled to pertussis toxin-sensitive G-proteins, which were identified as Gi2 and Gi3 by immunoblotting. The alpha-2 agonist was, moreover, able to decrease forskolin-stimulated cAMP production by 47% in HepG2 and 23% in SK-N-MC, demonstrating that inhibition of adenylyl cyclase is one of the primary mechanisms of signal transduction in both cell lines. HepG2 and SK-N-MC are the first human cell lines unquestionably shown to natively express alpha-2C adrenergic receptors. The discovery of these two models may be useful for future study of the regulation of α2C4 gene expression in cells of different origins and investigation of the reciprocal regulation ofalpha-2A and alpha-2C subtype in single cells.

Footnotes

  • Send reprint requests to: Dr. Hervé Paris, INSERM U317, Institut Louis Bugnard, CHU Rangueil, Bat. L3, 31054 Toulouse Cedex, France.

  • Abbreviations:
    bp
    base pair(s)
    cAMP
    cyclic AMP
    DMEM
    Dulbecco’s modified Eagle’s medium
    GppNHp
    5′-guanylylimidodiphosphate
    Hepes
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    MK912
    (2S,12bS)-1′,3′-dimethylspiro(1,3,4,5′,6,6′,7,12b-octahydro-2H-benzo[b]furo[2,3-a]quinazoline)-2,4′-pyrimidin-2′one
    ORF
    open reading frame
    PCR
    polymerase chain reaction
    RT
    reverse transcription
    RPA
    RNase protection assay
    RX821002
    2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline
    • Received September 20, 1996.
    • Accepted January 6, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 281, Issue 2
1 May 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
HepG2 and SK-N-MC: Two Human Models to StudyAlpha-2 Adrenergic Receptors of theAlpha-2C Subtype
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

HepG2 and SK-N-MC: Two Human Models to StudyAlpha-2 Adrenergic Receptors of theAlpha-2C Subtype

Stéphane Schaak, Cécile Cayla, Régis Blaise, Françoise Quinchon and Hervé Paris
Journal of Pharmacology and Experimental Therapeutics May 1, 1997, 281 (2) 983-991;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNEUROPHARMACOLOGY

HepG2 and SK-N-MC: Two Human Models to StudyAlpha-2 Adrenergic Receptors of theAlpha-2C Subtype

Stéphane Schaak, Cécile Cayla, Régis Blaise, Françoise Quinchon and Hervé Paris
Journal of Pharmacology and Experimental Therapeutics May 1, 1997, 281 (2) 983-991;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • KRM-II-81 Analogs
  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics